Mobile Gamma Cameras Market - Global Forecast 2026-2032

The Mobile Gamma Cameras Market size was estimated at USD 83.12 million in 2025 and expected to reach USD 89.42 million in 2026, at a CAGR of 7.77% to reach USD 140.38 million by 2032.

Mobile gamma cameras are increasingly important in nuclear medicine, radioguided surgery, emergency imaging, and point-of-care diagnostics because they enable functional imaging outside the constraints of fixed-camera suites. These portable gamma imaging systems detect gamma photons emitted by radiotracers to support localization of sentinel lymph nodes, parathyroid adenomas, thyroid tissue, bone lesions, infection sites, and other clinically relevant targets. Their value is most evident where rapid intraoperative confirmation, bedside imaging, workflow flexibility, and space-efficient deployment are priorities. Demand is being shaped by the global burden of cancer and cardiovascular disease, wider use of minimally invasive procedures, and healthcare systems seeking faster diagnostic pathways without compromising image quality or radiation safety. Advances in compact detector materials, solid-state sensors, collimator design, wireless connectivity, ergonomic form factors, and software-based image enhancement are expanding the clinical utility of mobile gamma cameras across hospitals, ambulatory surgical centers, specialty clinics, and research environments. Regulatory expectations remain rigorous because devices must meet standards for radiation detection accuracy, electrical safety, quality management, usability, and clinical performance. As healthcare providers move toward decentralized and patient-centered care, mobile gamma cameras are positioned as enabling technologies that improve access to nuclear imaging, support operating-room decision-making, and strengthen diagnostic efficiency in both mature and resource-constrained health systems.

The mobile gamma camera landscape is shifting from equipment portability alone toward integrated, workflow-driven nuclear imaging. Hospitals and surgical teams are increasingly adopting compact imaging devices that can be used in operating rooms, intensive care units, outpatient facilities, and procedure rooms, reducing dependence on fixed imaging infrastructure and improving patient throughput. Detector innovation is a central transformation, with solid-state technologies and improved scintillation systems supporting higher sensitivity, better spatial resolution, lower maintenance complexity, and more compact device footprints. Clinical protocols are also evolving, particularly in oncology and endocrine surgery, where real-time lesion localization and radiotracer-guided decisions can support tissue-sparing procedures and reduce re-exploration risk. Digitization is another defining shift: modern systems increasingly include image processing software, DICOM compatibility, connectivity with hospital information systems, and automated documentation capabilities. At the same time, procurement decisions are becoming more evidence-driven, with buyers evaluating total cost of ownership, staff training requirements, radiation safety governance, serviceability, and interoperability with existing nuclear medicine workflows. The industry is also responding to the growth of outpatient and same-day care models, where mobile gamma cameras can help providers extend advanced functional imaging beyond centralized departments while maintaining compliance with clinical and regulatory standards.

Artificial intelligence is beginning to reshape mobile gamma camera performance by improving image interpretation, acquisition efficiency, and workflow standardization. AI-enabled reconstruction, denoising, segmentation, and signal-to-noise optimization can help clinicians obtain more actionable images from compact systems, particularly when imaging time, patient positioning, or operating-room conditions are constrained. Machine learning tools may assist with lesion localization, anatomical correlation, motion correction, quality control, and automated reporting prompts, reducing variability across operators and care settings. The cumulative impact is especially relevant for intraoperative imaging, where rapid decisions depend on clear visual confirmation and accurate count-based guidance. AI can also support device calibration monitoring, predictive maintenance, protocol selection, and training simulations, helping facilities improve uptime and operational consistency. However, adoption depends on validation across diverse patient populations, transparent model performance, cybersecurity safeguards, explainability, and compliance with medical device regulations. AI in mobile gamma imaging should therefore be viewed as an augmentation layer rather than a replacement for clinical judgment. Its strongest near-term role is to enhance consistency, shorten learning curves, improve image usability, and support more reliable point-of-care nuclear medicine workflows.

Asia-Pacific is experiencing growing relevance for mobile gamma cameras as expanding cancer care infrastructure, investment in tertiary hospitals, and rising adoption of minimally invasive surgery increase demand for flexible nuclear imaging. Countries with advanced healthcare systems, including Japan, South Korea, Australia, and urban China, are better positioned to integrate compact gamma imaging into surgical oncology and specialty diagnostics, while emerging healthcare systems in South and Southeast Asia may benefit from portable systems that extend access where fixed nuclear medicine infrastructure is limited. North America remains a highly developed environment for mobile gamma camera adoption due to established nuclear medicine practices, strong surgical oncology programs, reimbursement structures for diagnostic imaging, and advanced hospital procurement processes. The United States and Canada emphasize evidence-based adoption, regulatory compliance, staff credentialing, and integration with operating-room and radiology workflows. Latin America shows selective but increasing opportunity, particularly in larger urban hospitals and oncology centers in Brazil and Mexico, where demand for cancer diagnostics and surgical efficiency is rising, although access can vary widely by public and private healthcare funding capacity. Europe demonstrates robust clinical awareness and regulatory discipline, with adoption influenced by hospital modernization, radiopharmaceutical availability, cross-border clinical standards, and growing emphasis on value-based care. Western European countries tend to have stronger installed nuclear medicine capabilities, while parts of Eastern and Southern Europe may prioritize cost-effective, multipurpose mobile platforms. The Middle East is supported by healthcare modernization programs, investment in oncology centers, and expansion of specialized hospitals, particularly in higher-income Gulf states where advanced imaging infrastructure is a strategic priority. Africa presents a more uneven landscape, with mobile gamma cameras offering practical value in settings where access to fixed nuclear medicine facilities is limited; however, broader adoption depends on radiotracer supply chains, trained nuclear medicine professionals, radiation safety frameworks, and sustainable equipment maintenance models.

ASEAN presents a diverse environment for mobile gamma cameras, with Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines at different stages of nuclear medicine infrastructure development. The group’s large patient populations, growing oncology burden, and expanding private hospital networks support interest in compact diagnostic and intraoperative imaging, while adoption is shaped by differences in radiopharmaceutical access, specialist training, and reimbursement maturity. The GCC is a strategically important group due to continued healthcare infrastructure investment, growth in tertiary and specialty hospitals, and national priorities focused on advanced cancer care, surgical innovation, and medical technology modernization. Mobile gamma cameras in GCC health systems can support operating-room efficiency and premium diagnostic services, particularly where hospitals seek to localize advanced care and reduce outbound medical travel. The European Union benefits from harmonized medical device regulation, strong clinical governance, and broad nuclear medicine expertise, making it a sophisticated environment for quality-assured mobile gamma imaging. EU adoption is influenced by hospital budget controls, procurement transparency, radiation protection directives, and demand for interoperable systems that support standardized clinical pathways. BRICS countries represent a high-variation group with substantial long-term relevance because of large populations, expanding hospital capacity, and growing cancer diagnostic needs. China and India provide scale and rapid healthcare infrastructure growth, Brazil and South Africa highlight regional access gaps and private-sector opportunities, and Russia maintains established specialty care capabilities in major urban centers. The G7 represents a mature technology and clinical standards environment where mobile gamma camera adoption is driven by evidence generation, workflow optimization, aging populations, oncology demand, and integration with digital health systems. NATO countries overlap with many advanced healthcare markets and include a broad base of hospitals, military medical services, and emergency preparedness systems, where mobile imaging can support flexible deployment, surgical readiness, and resilient diagnostic capacity.

The United States is one of the most advanced environments for mobile gamma cameras, supported by mature nuclear medicine departments, high surgical oncology volumes, rigorous device regulation, and strong adoption of operating-room technologies. Canada demonstrates steady relevance through its publicly funded healthcare system, emphasis on quality and safety, and need to improve diagnostic access across geographically dispersed populations. Mexico is increasingly important as oncology service capacity expands in major cities, with mobile gamma imaging offering value in private hospitals and referral centers seeking procedural efficiency. Brazil has one of Latin America’s more developed healthcare ecosystems and a significant cancer care burden, making compact gamma imaging relevant for tertiary hospitals, although regional disparities in access remain a constraint. The United Kingdom benefits from established nuclear medicine expertise, centralized clinical guidelines, and strong academic hospital networks, with mobile gamma cameras aligned to surgical precision and diagnostic workflow improvement. Germany is supported by advanced hospital infrastructure, engineering-focused procurement standards, and strong uptake of medical imaging technologies, while France combines mature nuclear medicine services with regulatory rigor and public health emphasis on cancer care. Russia has established nuclear medicine and oncology capabilities in major metropolitan centers, though procurement and modernization patterns can vary across regions. Italy and Spain present favorable clinical environments for mobile gamma cameras due to developed hospital networks, surgical oncology activity, and increasing focus on efficient patient pathways. China is highly significant because of rapid hospital expansion, increasing cancer diagnosis volumes, and ongoing investment in advanced imaging capacity, with adoption strongest in top-tier urban hospitals. India’s relevance is driven by a large patient base, expanding oncology infrastructure, and the need for cost-effective imaging access, though uneven radiopharmaceutical supply and specialist availability can influence deployment. Japan offers a technologically mature setting with advanced imaging practices, an aging population, and strong interest in precision diagnostics. Australia combines high clinical standards with geographic access challenges, making portable imaging relevant for specialized centers and potentially distributed care models. South Korea is characterized by advanced hospital systems, strong digital health integration, and high procedural sophistication, supporting adoption of compact gamma imaging in oncology and specialty surgical workflows.

Industry leaders should prioritize clinical evidence, workflow integration, and operational reliability when advancing mobile gamma camera strategies. Product development should focus on detector sensitivity, image clarity, intuitive user interfaces, ergonomic handling, battery performance, sterilization-compatible design, and seamless integration with hospital imaging and surgical information systems. Manufacturers and solution providers should invest in AI-assisted image enhancement and quality control only when supported by transparent validation, regulatory alignment, and robust cybersecurity. Commercial teams should tailor positioning by care setting: hospitals may prioritize interoperability and compliance, ambulatory surgical centers may value speed and usability, and resource-constrained facilities may require durable, serviceable, and cost-efficient systems. Training programs are essential because effective use depends on nuclear medicine coordination, radiotracer handling, radiation safety, operating-room protocols, and interpretation confidence. Leaders should also build partnerships with clinical educators, radiopharmacy networks, service organizations, and regulatory specialists to reduce implementation barriers. In emerging markets, success depends on practical deployment models that address maintenance, spare parts availability, staff training, and radiotracer logistics. Across all regions, the strongest competitive advantage will come from demonstrating measurable improvements in surgical confidence, diagnostic efficiency, patient flow, and quality assurance rather than emphasizing portability alone.

This executive summary is developed using a structured secondary research approach focused on verified, data-backed industry intelligence. The methodology synthesizes publicly available clinical literature, medical device regulatory guidance, nuclear medicine practice standards, hospital technology adoption trends, radiology and surgical workflow evidence, and regional healthcare infrastructure indicators. Sources considered include peer-reviewed medical publications, international health agencies, radiation safety and nuclear medicine organizations, regulatory authority documentation, healthcare policy references, and country-level healthcare system information. The analysis excludes market sizing, market share, revenue forecasting, and speculative growth estimates to maintain compliance with the requested scope. Regional, group, and country insights are interpreted through factors such as nuclear medicine maturity, oncology and surgical care capacity, availability of radiopharmaceuticals, regulatory readiness, hospital modernization, reimbursement environment, workforce capability, and access disparities. The methodology emphasizes cross-validation of themes rather than reliance on single-source claims, ensuring that conclusions reflect consistent, evidence-supported patterns across clinical, technological, and healthcare delivery contexts.

Mobile gamma cameras are becoming increasingly relevant as healthcare systems pursue faster, more flexible, and more precise nuclear imaging workflows. Their role extends beyond portability, supporting intraoperative decision-making, point-of-care diagnostics, and improved access to functional imaging in both advanced and developing healthcare environments. Technological progress in compact detectors, digital imaging, connectivity, and AI-assisted enhancement is strengthening their clinical value, while adoption remains dependent on radiotracer availability, workforce training, regulatory compliance, and integration with existing nuclear medicine pathways. Regional dynamics show mature adoption potential in North America, Europe, Japan, South Korea, and Australia, while Asia-Pacific, Latin America, the Middle East, and parts of Africa present selective opportunities shaped by healthcare investment and infrastructure readiness. For industry stakeholders, the path forward requires evidence-based product design, validated software intelligence, service reliability, and targeted implementation support. Organizations that align mobile gamma camera solutions with real clinical workflows, radiation safety requirements, and measurable care delivery improvements will be best positioned to support the next phase of portable nuclear medicine innovation.